August 18, 2011 -- WuXi PharmaTech plans to begin offering clinical trial CRO services to its clients, an addition to the company’s R&D and manufacturing offerings. The initiative comes at the request of its international clients, according to Ge Li, PhD, CEO of WuXi. Dr. Li said WuXi’s clients have asked for help conducting trials in China and then obtaining SFDA approval. More details....
Stock Symbol: (NYSE: WX)
